Clinical trial NCT03571334 - References

Peripheral Neuropathy Due to Chemotherapy — Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Citation(s)

•   Apfel SC
  Botulinum toxin for neuropathic pain? Neurology. 2009 Apr 28;72(17):1456-7. doi: 10.1212/WNL.0b013e3181a412b2. Epub 2009 Mar 25.
•   Argyriou AA, Bruna J, Marmiroli P, Cavaletti G
  Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012 Apr;82(1):51-77. doi: 10.1016/j.critrevonc.2011.04.012. Epub 2011 Sep 10. Review.
•   Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E
  Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005 Mar;114(1-2):29-36. Epub 2005 Jan 26.
•   Chen WT, Yuan RY, Chiang SC, Sheu JJ, Yu JM, Tseng IJ, Yang SK, Chang HH, Hu CJ
  OnabotulinumtoxinA improves tactile and mechanical pain perception in painful diabetic polyneuropathy. Clin J Pain. 2013 Apr;29(4):305-10. doi: 10.1097/AJP.0b013e318255c132.
•   Cui M, Khanijou S, Rubino J, Aoki KR
  Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33.
•   Fan C, Chu X, Wang L, Shi H, Li T
  Botulinum toxin type A reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain. Toxicon. 2017 Jul;133:116-122. doi: 10.1016/j.toxicon.2017.05.001. Epub 2017 May 3.
•   Favre-Guilmard C, Auguet M, Chabrier PE
  Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur J Pharmacol. 2009 Sep 1;617(1-3):48-53. doi: 10.1016/j.ejphar.2009.06.047. Epub 2009 Jul 1. Erratum in: Eur J Pharmacol. 2010 Feb 25;628(1-3):290.
•   Francisco GE, Tan H, Green M
  Do botulinum toxins have a role in the management of neuropathic pain?: a focused review. Am J Phys Med Rehabil. 2012 Oct;91(10):899-909. Review.
•   Freeman R, Wallace MS, Sweeney M, Backonja MM
  Relationships Among Pain Quality, Pain Impact, and Overall Improvement in Patients with Postherpetic Neuralgia Treated with Gastroretentive Gabapentin. Pain Med. 2015 Oct;16(10):2000-11. doi: 10.1111/pme.12791. Epub 2015 Jun 25.
•   Galer BS, Jensen MP
  Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology. 1997 Feb;48(2):332-8.
•   Ghasemi M, Ansari M, Basiri K, Shaigannejad V
  The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy. J Res Med Sci. 2014 Feb;19(2):106-11.
•   Jensen MP, Friedman M, Bonzo D, Richards P
  The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial. Clin J Pain. 2006 Jan;22(1):97-103.
•   Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL
  The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer. 2011 Nov;19(11):1769-77. doi: 10.1007/s00520-010-1018-3. Epub 2010 Oct 9.
•   Lakhan SE, Velasco DN, Tepper D
  Botulinum Toxin-A for Painful Diabetic Neuropathy: A Meta-Analysis. Pain Med. 2015 Sep;16(9):1773-80. doi: 10.1111/pme.12728. Epub 2015 Mar 20.
•   Lavoie Smith EM, Cohen JA, Pett MA, Beck SL
  The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums. Oncol Nurs Forum. 2011 Mar;38(2):133-42. doi: 10.1188/11.ONF.133-142.
•   Lucioni A, Bales GT, Lotan TL, McGehee DS, Cook SP, Rapp DE
  Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008 Feb;101(3):366-70. doi: 10.1111/j.1464-410X.2007.07312.x.
•   Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L
  Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014 Aug;22(8):2261-9. doi: 10.1007/s00520-014-2255-7. Epub 2014 May 1. Review.
•   Neumeister MW
  Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010 Dec;35(12):2085-92. doi: 10.1016/j.jhsa.2010.09.019.
•   Park HJ, Lee Y, Lee J, Park C, Moon DE
  The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth. 2006 May;53(5):470-7.
•   Park J, Park HJ
  Botulinum Toxin for the Treatment of Neuropathic Pain. Toxins (Basel). 2017 Aug 24;9(9). pii: E260. doi: 10.3390/toxins9090260. Review.
•   Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC
  Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15(29):3081-94. Review.
•   Poole HM, Murphy P, Nurmikko TJ
  Development and preliminary validation of the NePIQoL: a quality-of-life measure for neuropathic pain. J Pain Symptom Manage. 2009 Feb;37(2):233-45. doi: 10.1016/j.jpainsymman.2008.01.012. Epub 2008 Aug 3.
•   Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY; North Central Cancer Treatment Group
  Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007 Nov 1;110(9):2110-8.
•   Rostami R, Mittal SO, Radmand R, Jabbari B
  Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients. Toxins (Basel). 2016 Jan 13;8(1). pii: E22. doi: 10.3390/toxins8010022.
•   Segreto F, Marangi GF, Cerbone V, Persichetti P
  The Role of Botulinum Toxin A in the Treatment of Raynaud Phenomenon. Ann Plast Surg. 2016 Sep;77(3):318-23. doi: 10.1097/SAP.0000000000000715. Review.
•   Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M
  Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec;155(12):2461-2470. doi: 10.1016/j.pain.2014.09.020. Epub 2014 Sep 23. Review.
•   Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Hu CJ
  Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009 Apr 28;72(17):1473-8. doi: 10.1212/01.wnl.0000345968.05959.cf. Epub 2009 Feb 25.

Botulinum Toxin A for the Treatment of Chemotherapy Induced Peripheral Neuropathy

Details for clinical trial NCT03571334